Table 3

Effect of ω-3 fatty acid supplementation on plasma t-PA activity concentrations.

Substance P, pmol/minω-3 Fatty acidsPlacebo
02480248
t-PA activity, IU mL−1
 Non-infused arm0.39±0.080.45±0.090.54±0.120.64±0.140.45±0.070.52±0.080.60±0.090.65±0.11
 Infused arm0.38±0.080.83±0.161.12±0.231.67±0.380.43±0.070.78±0.101.09±0.111.26±0.15
t-PA antigen, ng mL−1
 Non-infused arm11.78±1.2912.01±1.012.69±1.0812.83±1.4913.45±1.4012.93±1.7013.08±1.8012.37±1.27
 Infused arm11.90±1.4513.98±1.3313.63±1.1214.86±1.4012.55±1.1012.85±1.4413.45±1.3513.97±1.55
PAI-1 activity, ng mL−1
 Non-infused arm1.77±0.531.84±0.431.80±0.421.64±0.451.44±0.291.38±0.261.39±0.471.34±0.44
 Infused arm2.33±0.862.18±0.612.21±0.691.92±0.631.69±0.461.64±0.411.54±0.391.49±0.39
PAI-1 antigen, ng mL−1
 Non-infused arm39.51±9.2240.84±7.0839.99±6.6238.48±5.7945.06±7.0943.33±6.4544.41±6.6744.26±7.03
 Infused arm37.64±8.3638.83±6.2541.71±5.7440.26±7.3248.89±8.2542.65±6.5943.12±6.6040.61±6.46
Net t-PA antigen release, ng 100 mL−1 of tissue mm−10.23±0.51−0.28±4.73.92±1.88.41±2.94−0.87±1.1−0.84±2.820.94±4.228.10±3.67
  • Mean±SEM. Data analysed using two-way analysis of variance.

  • Tissue plasminogen activator (t-PA) activity: dose response p<0.0001. ω-3 Fatty acids versus placebo; p=0.83 (infused arm).

  • t-PA antigen: dose response p=0.7. ω-3 Fatty acids versus placebo; p=0.60 (infused arm).

  • Plasminogen-activator inhibitor type 1 (PAI-1) activity: dose response p=0.94. ω-3 Fatty acids versus placebo; p=0.17 (infused arm).

  • PAI-1 antigen: dose response p=0.67. ω-3 Fatty acids versus placebo; p=0.40 (infused arm).

  • Net t-PA antigen: dose response p=0.02. ω-3 Fatty acids versus placebo; p=0.62 (infused arm).